Carcinome adrénocortical (CAC) · ligne 1 · Mitotane adjuvant en monothérapie (CAC)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.

Source YAML: dossier complet

Ligne thérapeutique	1
Voie	standard
Régime lié	`REG-MITOTANE-ADJUVANT-ACC`

ID	`IND-ACC-1L-RESECTION-MITOTANE`
Type	Indication
État	reviewed 2026-07-11 \| pending_clinical_signoff
Maladies	`DIS-ADRENOCORTICAL-CARCINOMA`
Sources	`SRC-ADIUVO-TERZOLO-2023` `SRC-ENSAT-ACC-2018` `SRC-ESMO-ACC-2020` `SRC-NCCN-NET-2025`

Notes

STUB pending clinical co-lead sign-off (CHARTER §6.1). Authored to close the DIS-ADRENOCORTICAL-CARCINOMA v0.1 content gap (metadata.awaiting_proposal). "High recurrence risk" is operationalized via RF-ACC-HIGH-RECURRENCE-RISK-BIOLOGY (stage III / Ki-67 >10% / R1-RX margin), itself a first-pass reading of ADIUVO's low/intermediate-risk enrollment criteria in reverse — pending clinical co-lead confirmation against the primary ENSAT/ESMO guideline text, which may specify additional risk factors (e.g. tumor rupture, vascular invasion) not yet encoded. Lower-risk resected patients (surveillance-alone candidates per ADIUVO) are intentionally NOT covered by this Indication — see ALGO-ACC-1L step 2 null-branch. Surgery is described in prose (rationale/stage_requirements) rather than via a Surgery-entity FK/ phases: structure — no adrenalectomy Surgery entity exists in this KB and authoring one is out of scope for this task.

Utilisé par

Algorithmes

ALGO-ACC-1L - ALGO-ACC-1L

Médicament

DRUG-MITOTANE - Mitotane

Sources

SRC-ADIUVO-TERZOLO-2023 - Mitotane adjuvant versus surveillance chez le carcinome adrénocortical localisé de faible grade (A...